Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Feasibility Trial of MK3475 + Docetaxel or Gemcitabine in Platinum Pre-treated Urothelial Cancer

NCT02437370 is registered in ClinicalTrials.gov with University of California, Davis as lead sponsor.

NCT NCT02437370
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02437370 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Feasibility Trial of MK3475 + Docetaxel or Gemcitabine in Platinum Pre-treated Urothelial Cancer
Lead sponsor
University of California, Davis
Phase
Phase 1
Overall status
Completed
Start date
September 1, 2015
Completion date
March 10, 2020
Enrollment
32 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic urothelial carcinoma of the renal pelvis and ureter, recurrent bladder carcinoma, recurrent urothelial carcinoma of the renal pelvis and ureter, regional urothelial carcinoma of the renal pelvis and ureter, stage iii bladder urothelial carcinoma, stage iii urethral cancer, stage iv bladder urothelial carcinoma, stage iv urethral cancer, urethral urothelial carcinoma